Literature DB >> 26305037

Haematological cancer: Resiquimod—a topical CTCL therapy.

David Killock.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26305037     DOI： 10.1038/nrclinonc.2015.142

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma.

Authors:  Alain H Rook; Joel M Gelfand; Joel C Gelfand; Maria Wysocka; Andrea B Troxel; Bernice Benoit; Christian Surber; Rosalie Elenitsas; Marie A Buchanan; Deborah S Leahy; Rei Watanabe; Ilan R Kirsch; Ellen J Kim; Rachael A Clark
Journal:  Blood       Date:  2015-07-30       Impact factor: 22.113
  1 in total
  4 in total

1.  The TLR7/8 agonist R848 optimizes host and tumor immunity to improve therapeutic efficacy in murine lung cancer.

Authors:  Jianchun Zhou; Yu Xu; Guansong Wang; Tonghua Mei; Hao Yang; Yuliang Liu
Journal:  Int J Oncol       Date:  2022-05-13       Impact factor: 5.884

2.  Immunomodulation in Cutaneous T Cell Lymphoma.

Authors:  Martina Ferranti; Giulia Tadiotto Cicogna; Irene Russo; Mauro Alaibac
Journal:  Front Oncol       Date:  2019-10-09       Impact factor: 6.244

Review 3.  Trial Watch: experimental TLR7/TLR8 agonists for oncological indications.

Authors:  Giorgio Frega; Qi Wu; Julie Le Naour; Erika Vacchelli; Lorenzo Galluzzi; Guido Kroemer; Oliver Kepp
Journal:  Oncoimmunology       Date:  2020-07-21       Impact factor: 8.110

Review 4.  Trial watch: TLR3 agonists in cancer therapy.

Authors:  Julie Le Naour; Lorenzo Galluzzi; Laurence Zitvogel; Guido Kroemer; Erika Vacchelli
Journal:  Oncoimmunology       Date:  2020-06-02       Impact factor: 8.110
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.